Retina/Vitreous News

OcuTerra Therapeutics is evaluating strategic alternatives after the phase 2 DR:EAM trial failed to meet its primary efficacy endpoint, according to a press release.

Exonate has announced successful safety and tolerability data from its phase 1b/2a trial of EXN407, a topical small-molecule therapeutic for retinal vascular diseases, such as diabetic retinopathy and diabetic macular edema.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Karl G. Stonecipher, MD, discusses newer treatments and thought processes in diagnostics in artificial intelligence in dry eye disease.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Lejla Vajzovic, MD, FASRS, discusses developments in gene therapy for wet age-related macular degeneration.

Traumatic optic nerve head avulsion and traumatic optic neuropathy are serious and can be visually devastating. Most cases have poor prognosis for visual recovery, leaving patients with minimal or no vision in the affected eye.

Sandoz has completed the acquisition of Cimerli, a ranibizumab biosimilar, from Coherus BioSciences, according to a press release.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Daniel Zhu, MD, discusses outcomes of chandelier-assisted scleral buckling in rhegmatogenous retinal detachments.

ATLANTA — Ocuphire Pharma shared the status of its oral nonproliferative diabetic retinopathy treatment, APX3330, with the optometry community at SECO 2024.

Age-related macular degeneration can occur even in patients without a family history, so clinicians must be aware of early warning signs of the disease, according to Deborah Ferrington, PhD.

PulseSight Therapeutics, which is developing non-viral gene therapies for retinal diseases, has launched with seed financing from Pureos Bioventures and ND Capital, according to a press release.